Doron Boltin1,2, Zvi Kamenetsky3, Tsachi Tsadok Perets4, Yifat Snir5, Boris Sapoznikov3, Hemda Schmilovitz-Weiss3,6, Jacob Nadav Ablin7,6, Ram Dickman5,6, Yaron Niv5,6. 1. Division of Gastroenterology, Rabin Medical Center, Belinson Campus, 39 Jabotinski Street, 49100, Petah Tikva, Israel. dboltin@gmail.com. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. dboltin@gmail.com. 3. Department of Gastroenterology, Rabin Medical Center, HaSharon Campus, Petah Tikva, Israel. 4. Gastroenterology Laboratory, Department of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel. 5. Division of Gastroenterology, Rabin Medical Center, Belinson Campus, 39 Jabotinski Street, 49100, Petah Tikva, Israel. 6. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 7. Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Abstract
BACKGROUND: Circulating endothelial progenitor cells (EPCs) are bone marrow-derived stem cells able to migrate to sites of damaged endothelium and differentiate into endothelial cells. Altered EPC level and function have been described in various inflammatory diseases and have been shown to augment vasculogenesis in murine models. Previous studies of EPC in the context of Crohn's disease (CD) have yielded conflicting results. AIM: To determine whether the circulating levels of EPCs are changed in the context of CD. METHODS: CD patients and healthy controls were recruited. Disease activity was assessed by CDAI. Peripheral blood mononuclear cells were isolated and EPC numbers evaluated by FACS analysis using anti-CD34, anti-VEGF receptor-2, anti-CD133, and anti-CD45 markers. RESULTS: Eighty-three subjects, including 32 CD patients and 51 controls were recruited, including 19 (59.4 %) and 23 (45 %) males (p = 0.26), aged 34.8 ± 14.9 and 43.3 ± 18.5 years (p = 0.64), in cases and controls, respectively. Mean CDAI was 147 ± 97, disease duration was 12.7 ± 11.1 years, and 28 (87.5 %) were receiving biologics for a mean duration of 21.7 ± 16.8 months. The mean level of peripheral EPCs in CD patients was 0.050 ± 0.086 percent and 0.007 ± 0.013 % in controls (p < 0.01). There was no significant correlation between EPC levels and age (r = -0.13, p = 0.47), CDAI (r = -0.26, p = 0.15), disease duration (r = -0.04, p = 0.84), or duration of treatment with biologics (r = 0.004, p = 0.99). CONCLUSION: EPCs are elevated in patients with CD. Further studies are needed to examine the function of EPCs and their possible role as a marker of disease severity or therapeutic response.
BACKGROUND: Circulating endothelial progenitor cells (EPCs) are bone marrow-derived stem cells able to migrate to sites of damaged endothelium and differentiate into endothelial cells. Altered EPC level and function have been described in various inflammatory diseases and have been shown to augment vasculogenesis in murine models. Previous studies of EPC in the context of Crohn's disease (CD) have yielded conflicting results. AIM: To determine whether the circulating levels of EPCs are changed in the context of CD. METHODS:CDpatients and healthy controls were recruited. Disease activity was assessed by CDAI. Peripheral blood mononuclear cells were isolated and EPC numbers evaluated by FACS analysis using anti-CD34, anti-VEGF receptor-2, anti-CD133, and anti-CD45 markers. RESULTS: Eighty-three subjects, including 32 CDpatients and 51 controls were recruited, including 19 (59.4 %) and 23 (45 %) males (p = 0.26), aged 34.8 ± 14.9 and 43.3 ± 18.5 years (p = 0.64), in cases and controls, respectively. Mean CDAI was 147 ± 97, disease duration was 12.7 ± 11.1 years, and 28 (87.5 %) were receiving biologics for a mean duration of 21.7 ± 16.8 months. The mean level of peripheral EPCs in CDpatients was 0.050 ± 0.086 percent and 0.007 ± 0.013 % in controls (p < 0.01). There was no significant correlation between EPC levels and age (r = -0.13, p = 0.47), CDAI (r = -0.26, p = 0.15), disease duration (r = -0.04, p = 0.84), or duration of treatment with biologics (r = 0.004, p = 0.99). CONCLUSION: EPCs are elevated in patients with CD. Further studies are needed to examine the function of EPCs and their possible role as a marker of disease severity or therapeutic response.
Authors: Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes Journal: Gut Date: 2010-10-04 Impact factor: 23.059
Authors: Andrea Garolla; Renata D'Incà; Davide Checchin; Andrea Biagioli; Luca De Toni; Valentina Nicoletti; Marco Scarpa; Elisa Bolzonello; Giacomo Carlo Sturniolo; Carlo Foresta Journal: Am J Gastroenterol Date: 2009-06-30 Impact factor: 10.864
Authors: U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler Journal: Blood Date: 2000-05-15 Impact factor: 22.113
Authors: Thomas J Povsic; Candice Junge; Adel Nada; Richard A Schatz; Robert A Harrington; Charles J Davidson; F David Fortuin; Dean J Kereiakes; Farrell O Mendelsohn; Warren Sherman; Gary L Schaer; Christopher J White; Duncan Stewart; Kenneth Story; Douglas W Losordo; Timothy D Henry Journal: Am Heart J Date: 2013-04-19 Impact factor: 4.749
Authors: Jakub Závada; Linda Kideryová; Robert Pytlík; Zdenka Vanková; Vladimír Tesar Journal: Kidney Blood Press Res Date: 2008-07-04 Impact factor: 2.687
Authors: Douglas W Losordo; Melina R Kibbe; Farrell Mendelsohn; William Marston; Vickie R Driver; Melhem Sharafuddin; Victoria Teodorescu; Bret N Wiechmann; Charles Thompson; Larry Kraiss; Teresa Carman; Suhail Dohad; Paul Huang; Candice E Junge; Kenneth Story; Tara Weistroffer; Tina M Thorne; Meredith Millay; John Paul Runyon; Robert Schainfeld Journal: Circ Cardiovasc Interv Date: 2012-11-27 Impact factor: 6.546